InvestorsHub Logo
Post# of 252642
Next 10
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 105110

Sunday, 10/17/2010 9:49:12 AM

Sunday, October 17, 2010 9:49:12 AM

Post# of 252642
IDIX 2010-2011 News Flow

[Updated phase-2b lineup for IDX899.]


HCV

Oct 2010/AASLD: Present complete datasets from IDX184, IDX320, and IDX375 studies for which top-line data was reported in IDIX’s 9/7/10 PR (#msg-54120531).

4Q10: Start IDX375 phase-1b 3-day monotherapy trial.

Late 2010/early 2011: Possible lifting of clinical hold on IDX184 and/or IDX320 programs following FDA review of combination animal-tox study and all clinical data to date.

Late 2010: Select lead NS5A compound. Start phase-1 trial in 1H11.


HIV

4Q10: GSK enrolls first patient in phase-2b SONNET trial, which will generate a significant milestone payment for IDIX from GSK (#msg-55627169, #msg-49743057).

Early 2011: GSK start IDX899 phase-2b trial in first-line setting, testing IDX899+Truvada vs Sustiva+Truvada.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.